{"organizations": [], "uuid": "c09b39bc06f3e4aa5a05a4cb54e9f5df4aff9eae", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180206.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-lysogene-gets-green-light-from-eur/brief-lysogene-gets-green-light-from-european-medicines-agency-on-mps-iiia-pivotal-study-idUSFWN1PW114", "country": "US", "domain_rank": 408, "title": "BRIEF-Lysogene Gets Green Light From European Medicines Agency On MPS IIIA Pivotal Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.261, "site_type": "news", "published": "2018-02-07T00:54:00.000+02:00", "replies_count": 0, "uuid": "c09b39bc06f3e4aa5a05a4cb54e9f5df4aff9eae"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-lysogene-gets-green-light-from-eur/brief-lysogene-gets-green-light-from-european-medicines-agency-on-mps-iiia-pivotal-study-idUSFWN1PW114", "ord_in_thread": 0, "title": "BRIEF-Lysogene Gets Green Light From European Medicines Agency On MPS IIIA Pivotal Study", "locations": [], "entities": {"persons": [{"name": "lysogene", "sentiment": "negative"}], "locations": [{"name": "eu", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "green light from european medicines agency", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 6 (Reuters) - LYSOGENE SA:\n* LYSOGENE GETS PIP GREEN LIGHT FROM EUROPEAN MEDICINES AGENCY ON MPS IIIA PIVOTAL STUDY; PAVING WAY FOR CLINICAL TRIAL APPLICATION APPROVALS\n* ‍SUCCESSFUL PIP COMPLIANCE CHECK EXTENDS MARKET EXCLUSIVITY TO 12 YEARS AT EU MARKET AUTHORIZATION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-07T00:54:00.000+02:00", "crawled": "2018-02-07T22:13:43.003+02:00", "highlightTitle": ""}